An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia.

Trial Profile

An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Lirilumab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Innate Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jul 2014 Planned End Date changed from 1 Sep 2013 to NULL.
    • 27 Feb 2014 Status of the extension trial changed from active, no longer recruiting to completed as per ClinicalTrials.gov record as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top